Protective effect of astragalosides on kidney damage in diabetic mice

Abstract

Abstract:

AIM: To study the effect of astragalosides (AST) on kidney damage and the mechanism in diabetic mice. METHODS: The diabetic mice model was established by intraperitoneal injection with STZ and the model mice were randomly divided into model group, tempol group, AST-L group, AST-M group, and AST-H group. After 4 weeks and 6 weeks of administration, concentration of fasting blood glucose (FBG) and glycosylated serum protein (GSP) were recorded; weight and kidney indexes were calculated; renal pathological changes were observed; glomerular apoptosis and renal TGF-beta 1, Col Ⅳ mRNA expressions were detected by TUNEL and RT-PCR method, respectively. RESULTS: AST can significantly reduce the levels of serum FBG and GSP of diabetic mice induced by STZ in time and dose dependent way (P<0.01). After 6 weeks of administration, the body weight increased, while the kidney index, glomerulus defects and cell apoptosis decreased in all treatment group(P<0.01). Compared with model group, the high expression of Col Ⅳ mRNA and TGF-β1 mRNA were significantly decreased in kidney of AST 60 mg/kg dose group (P<0.05). CONCLUSION: There are some protective effects of AST on kidney of experimental diabetic mice, and its mechanism may be related to promote kidney Col Ⅳ, TGF-beta 1mRNA expression.

Key words: diabetes mellitus, astragalosides, Col Ⅳ, TGF-β1

CLC Number:

R965.2

LIU Xiaoyun, ZHANG Wen, LI Weiping, GONG Huilin, HAN Jia, LUAN Jiajie. Protective effect of astragalosides on kidney damage in diabetic mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 132-138.

References

［1］李晓萍,李进, 黄学宽.楂芪降糖汤对糖尿病肾病大鼠肾脏 TGF-β1及VEGF 表达的影响［J］. 中成药,2013,35(3):450-455.
［2］Araki S, Haneda M, Koya D, et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria［J］.Diabetes Care, 2010, 33(8):1805-1810.
［3］郝萌萌,李蕾,陈志红,等. 黄芪对小鼠胰岛炎及胰岛B细胞凋亡的保护作用［J］. 中华实用儿科临床杂志，2013,28(8): 577-580.
［4］王春怡,陈艳芬,李卫民,等. 黄芪葛根汤对实验性糖尿病及胰岛素抵抗的影响［J］. 中国实验方剂学杂志,2011,17(16):144-149.
［5］黄可儿, 赵敏,王建华.黄芪总苷的药理研究进展［J］. 中药新药与临床药理, 2005,16(6):461-463.
［6］Xiang FL, Lu X, Strutt B, et al.NOX2 deficiency protects against streptozotocin-induced beta-cell destruction and development of diabetes in mice［J］. Diabetes, 2010, 59(10):2603-2611.
［7］Zhang X, He H, Liang D, et al. Protective effects of berberine on renal injury in streptozotocin (STZ)-induced diabetic mice［J］. Int J Mol Sci, 2016, 17(8):E1327.
［8］Xu L, Shen P, Bi Y, et al. Danshen injection ameliorates STZ-induced diabetic nephropathy in association with suppression of oxidative stress, pro-inflammatory factors and fibrosis［J］. Int Immunopharmacol, 2016, 38:385-394.
［9］傅晓骏,熊荣兵.黄芪水蛭制剂对糖尿病肾病大鼠 TGF-β1表达的实验研究［J］. 中国中医急症,2012,21(10):1595-1597.
［10］李凤婷，李梦，王馨瑶，等．固本通络汤对糖尿病肾病模型大鼠 TGF-β1、MMP-9、TIMP-1 表达的影响［J］. 首都医科大学学报,2014,35( 1) : 118-121．
［11］孔慧乎，兰丽珍. Exendin-4干预对糖尿病肾病大鼠肾脏TGF-β1 mRNA和蛋白表达的影响［J］.中西医结合心脑血管病杂志,2012,10(2):204-206.
［12］Lee SY, Kim SI, Choi ME. Therapeutic targets for treating fibrotic kidney diseases［J］.Transl Res,2015,165(4):512-530.
［13］傅晓骏，熊荣兵. 黄芪水蛭制剂对糖尿病肾病大鼠肾组织中C -IV、FN 及 IL- 1β表达的实验研究［J］. 中华中医药学刊,2013,31(2):305-308.
［14］Prakash J. Non-diabetic renal disease (NDRD) in patients with type 2 diabetes mellitus (type 2 DM) ［J］. J Assoc Physicians India, 2013, 61(3):194-199.
［15］陶松桔, 尹支农, 徐自强, 等. 黄芪注射液对糖尿病肾病患者血Ⅳ型胶原与转化生长因子-β1水平的影响及其意义［J］. 中国综合临床, 2004,20(3):217-219.
［16］王颖航,牛英才,王颖,等. 消癥散结扶正活络方药对 TGF-β1诱导的HMCs 增殖及Ⅳ型胶原分泌的影响［J］. 时珍国医国药, 2012, 23 (6):1335-1336.
［17］Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice ［J］. Proc Natl Acad Sci USA,2000,97(14):8015-8020.
［18］罗旭光. 黄芪治疗糖尿病肾病的疗效及安全性分析［J］. 中医临床研究,2015,7(8):29-30.
［19］张杰生,张童茜,安宏. 黄芪在心血管疾病治疗中的应用进展［J］. 中医研究,2012,25(8):78-80.
［20］Ranjbar A, Ghasemi H, Hatami M, et al. Tempol effects on diabetic nephropathy in male rats［J］. J Renal Inj Prev, 2016, 5(2):74-78.
［21］Rodriguez F, Lopez B, Perez C, et al. Chronic tempol treatment attenuates the renal hemodynamic effects induced by a heme oxygenase inhibitor in streptozotocin diabetic rats［J］. Am J Physiol Regul Integr Comp Physiol, 2011, 301(5):R1540-1548.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[4]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[5]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[6]	WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
[7]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[8]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[9]	HUANG Hao, XIAO Fang, JIA Hong, WANG Xiaoshuang, DUAN Yating. miR-138-5p protects β cell function by regulating HIF-1α in gestational diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 489-497.
[10]	ZHANG Xiaoling，GUAN Qiaobin，YANG Yi, GUO Li，HAN Chenyang. Effect of interleukin 12A on proliferation and differentiation of CD4+CD25+Foxp3+Treg [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 496-502.
[11]	HE Yang, SONG Liying, PENG Xiangdong, FANG Weijin, WANG Chunjiang, DENG Zhenzhen, LIU Shikun. Protective effects of Cordyceps sinensis powder on liver injury induced by DEN in rats and the effect of TGF-β1/Smads pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 974-982.
[12]	YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.
[13]	CHENG Xiaolong, HU Kunmei, HU Haoran，XU Hanghang, YANG Jieren, HAN Jun. Effects of Chinese medicine Yuxia capsule on renal fibrosis in spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 632-639.
[14]	XU Ming, SHEN Zheng. Research progress on the mechanism of traditional Chinese insects' medicine treatment of diabetic neurological complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 597-600.
[15]	LI Zhuqing, JU Yinghui, CHEN Qingqing, MA Keke, LI Weiping. Protective effects of Astragaloside Ⅳ on early kidney damage in diabetes mellitus rats and its mechanisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 255-262.